FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095694080> ?p ?o ?g. }

• W2095694080 endingPage "S43" @default.
• W2095694080 startingPage "S35" @default.
• W2095694080 abstract "Host conditioning prior to allogeneic bone marrow transplantation (BMT) has traditionally involved the use of high-dose, myeloablative chemotherapy and irradiation, focusing on maximal tumor cytoreduction as well as adequate immunosuppression to allow engraftment of allogeneic stem cells. High-dose chemoradiation conditioning regimens have been associated with a significant incidence of organ toxicity and acute and chronic graft-versus-host disease (GVHD). Recent efforts to diminish the acute transplant-associated toxicities have focused on the development of relatively nontoxic, nonmyeloablative, or less myeloablative conditioning regimens, with the emphasis being predominantly on induction of immunosuppression to enable engraftment. Without ablative chemotherapy, disease control in these regimens is largely relegated to the graft-versus-leukemia/lymphoma (GVL) effect. While the evolution these regimens has resulted in successful engraftment of allogeneic stem cells with minimal toxicity, acute and chronic GVHD occurs in 20% to 50% of patients and remains a major cause of transplant-associated morbidity. Strategies to lower the incidence of acute GVHD have primarily focused on more precise molecular donor/recipient matching, alternative stem cell sources, and T-cell depletion of the graft. While successful in lowering the frequency and severity of GVHD, T-cell-depleted grafts have been associated with compromised the graft-versus-disease effect. Recent studies have suggested that, in addition to T-effector cells within the graft, donor and host dendritic cells may play a role in GVHD. Purine analogues have been evaluated as part of these regimens. While fludarabine and cladribine have been shown to be effective, these agents have been associated with an increased incidence of serious infection and severe acute GVHD. Pentostatin has a different mechanism of action and was also investigated as part of these preparative regimens. Regimens using pentostatin/extracorporeal photopheresis (ECP)/total body irradiation (TBI) have been shown to be well tolerated and associated with early full donor engraftment with a predominance of donor dendritic cell (DC)2 cells and a low incidence of acute GVHD. Further investigation evaluating this preparative regimen is warranted." @default.
• W2095694080 created "2016-06-24" @default.
• W2095694080 creator A5048583088 @default.
• W2095694080 date "2006-04-01" @default.
• W2095694080 modified "2023-09-27" @default.
• W2095694080 title "The Role of Purine Analogues in Low-Intensity Regimens With Allogeneic Hematopoietic Stem Cell Transplantation" @default.
• W2095694080 cites W1479909146 @default.
• W2095694080 cites W1508187469 @default.
• W2095694080 cites W1517291270 @default.
• W2095694080 cites W1518533450 @default.
• W2095694080 cites W1547120987 @default.
• W2095694080 cites W1596160021 @default.
• W2095694080 cites W1864748840 @default.
• W2095694080 cites W1883328448 @default.
• W2095694080 cites W1966948793 @default.
• W2095694080 cites W1968537886 @default.
• W2095694080 cites W1970394014 @default.
• W2095694080 cites W1970576650 @default.
• W2095694080 cites W1993231178 @default.
• W2095694080 cites W1994078412 @default.
• W2095694080 cites W1997558956 @default.
• W2095694080 cites W1999514386 @default.
• W2095694080 cites W1999545570 @default.
• W2095694080 cites W2010642626 @default.
• W2095694080 cites W2011197626 @default.
• W2095694080 cites W2018953740 @default.
• W2095694080 cites W2021977368 @default.
• W2095694080 cites W2025457437 @default.
• W2095694080 cites W2029303244 @default.
• W2095694080 cites W2038155466 @default.
• W2095694080 cites W2041438140 @default.
• W2095694080 cites W2058809104 @default.
• W2095694080 cites W2061325374 @default.
• W2095694080 cites W2062506977 @default.
• W2095694080 cites W2066885693 @default.
• W2095694080 cites W2067564880 @default.
• W2095694080 cites W2071104756 @default.
• W2095694080 cites W2076724485 @default.
• W2095694080 cites W2081783577 @default.
• W2095694080 cites W2087591188 @default.
• W2095694080 cites W2102443829 @default.
• W2095694080 cites W2106947293 @default.
• W2095694080 cites W2107412758 @default.
• W2095694080 cites W2126484153 @default.
• W2095694080 cites W2127036836 @default.
• W2095694080 cites W2132589242 @default.
• W2095694080 cites W2137632045 @default.
• W2095694080 cites W2149131140 @default.
• W2095694080 cites W2161503027 @default.
• W2095694080 cites W2242587738 @default.
• W2095694080 cites W2325115734 @default.
• W2095694080 cites W2328776376 @default.
• W2095694080 cites W2411653119 @default.
• W2095694080 cites W2559634259 @default.
• W2095694080 cites W275233436 @default.
• W2095694080 cites W287410142 @default.
• W2095694080 cites W4236768471 @default.
• W2095694080 cites W4246085869 @default.
• W2095694080 cites W4251093572 @default.
• W2095694080 cites W4251178308 @default.
• W2095694080 cites W86178059 @default.
• W2095694080 doi "https://doi.org/10.1053/j.seminhematol.2005.12.007" @default.
• W2095694080 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16549113" @default.
• W2095694080 hasPublicationYear "2006" @default.
• W2095694080 type Work @default.
• W2095694080 sameAs 2095694080 @default.
• W2095694080 citedByCount "11" @default.
• W2095694080 countsByYear W20956940802012 @default.
• W2095694080 countsByYear W20956940802014 @default.
• W2095694080 countsByYear W20956940802017 @default.
• W2095694080 crossrefType "journal-article" @default.
• W2095694080 hasAuthorship W2095694080A5048583088 @default.
• W2095694080 hasConcept C109246011 @default.
• W2095694080 hasConcept C126322002 @default.
• W2095694080 hasConcept C143998085 @default.
• W2095694080 hasConcept C181199279 @default.
• W2095694080 hasConcept C203014093 @default.
• W2095694080 hasConcept C2776476023 @default.
• W2095694080 hasConcept C2776694085 @default.
• W2095694080 hasConcept C2776755627 @default.
• W2095694080 hasConcept C2777408962 @default.
• W2095694080 hasConcept C2779263901 @default.
• W2095694080 hasConcept C2779972918 @default.
• W2095694080 hasConcept C2780252810 @default.
• W2095694080 hasConcept C28328180 @default.
• W2095694080 hasConcept C2911091166 @default.
• W2095694080 hasConcept C54355233 @default.
• W2095694080 hasConcept C55493867 @default.
• W2095694080 hasConcept C71924100 @default.
• W2095694080 hasConcept C86803240 @default.
• W2095694080 hasConceptScore W2095694080C109246011 @default.
• W2095694080 hasConceptScore W2095694080C126322002 @default.
• W2095694080 hasConceptScore W2095694080C143998085 @default.
• W2095694080 hasConceptScore W2095694080C181199279 @default.
• W2095694080 hasConceptScore W2095694080C203014093 @default.
• W2095694080 hasConceptScore W2095694080C2776476023 @default.
• W2095694080 hasConceptScore W2095694080C2776694085 @default.
• W2095694080 hasConceptScore W2095694080C2776755627 @default.

• next